CGEN
CompugenANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that the Q1 filing confirms the balance sheet is intact, MAIA-ovarian enrollment is progressing, and the company still has a clear binary event by Q1 2027; if the interim readout is constructive and partner programs keep advancing, the stock can work toward the packet's $4.0 median target.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
AstraZeneca/Gilead optionality is valuable, but milestone and royalty timing remains uncertain.
Momentum
89
Value
47
Sentiment
95
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.50 · Bull $5.00 · Bear $1.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $4.00
Why
Momentum89 · Δ7d -
Value47 · Δ7d +0.1
Sentiment95 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
89
34% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
47
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
95
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 89.1 / Value 47.2 / Sentiment 95.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$232.6M
Beta
1.61
Shares Out
93.54M
P/E (TTM) · Derived
6.6
P/S (TTM)
21.00
P/FCF (TTM)
2.93
Rev YoY
-89.0%
EPS YoY
-625.1%
Gross Margin
+7.4%
Op Margin
-466.5%
Net Debt
-$103.3M
Current Ratio
4.38
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology